Previous 10 | Next 10 |
2023-04-14 14:30:56 ET Earnings season heats up in mid-April with a host of earnings results due from the likes of Tesla ( NASDAQ: TSLA ), Netflix ( NFLX ), Johnson & Johnson ( JNJ ), Lockheed Martin ( LMT ), and a host of financial giants. Bank of America ( BAC ...
2023-04-14 13:30:11 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch for a full list of events planned for the week or the Seeking Alpha earnings calendar for com...
2023-04-14 05:32:00 ET Ghana became the first country globally to approve a new malaria vaccine developed by the Oxford University, BBC reported. Ghana's Food and Drugs Authority approved the vaccine, dubbed R21, for use in children between five months to three years old. The Africa...
2023-04-13 21:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-04-13 05:02:47 ET A federal appeals court blocked part of a Texas court's ruling that would halt the access to the abortion pill mifepristone. Earlier this week, the U.S. Justice Department (DOJ) had asked the U.S. 5th Circuit Court of Appeals to halt U.S. Judge Matthew Kacsmar...
2023-04-12 08:35:13 ET Denali Therapeutics ( NASDAQ: DNLI ) added ~3% pre-market Wednesday in reaction to Biogen’s ( NASDAQ: BIIB ) decision to excise an option to license the company’s Antibody Transport Vehicle (ATV): Amyloid beta program (ATV:Aβ...
CAMBRIDGE, Mass. and SOUTH SAN FRANCISCO, Calif., April 12, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that Biogen has exercised the option to license Denali’s Antibody Transport Vehicle (ATV):Amyloid beta program (AT...
2023-04-12 02:26:28 ET Summary The White House's announcement on drug price caps caused a significant drop in biopharma stocks during Q1 2023. The impact of drug pricing-related caps and pressure will likely be limited, and the industry is expected to adapt and find new revenue st...
2023-04-10 13:53:43 ET The FDA announced Monday that an advisory committee would meet on June 09, 2023, to discuss the marketing application for Leqembi (lecanemab), developed by Biogen ( NASDAQ: BIIB ) and Eisai ( OTCPK:ESALF ) ( OTCPK:ESAIY ) as a treatment for Alzheimer...
2023-04-06 12:35:54 ET FDA’s accelerated drug approval program came under scrutiny on Thursday after the agency withdrew its approval for Makena, a drug first cleared the regulatory hurdle more than a decade ago to prevent preterm birth in women. The FDA approved Makena in 2011 u...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases ...
TOKYO and CAMBRIDGE, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today tha...
NEW YORK, NY / ACCESSWIRE / June 12, 2024 / Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (Nasdaq:BIIB) Securities Class Action Lawsuit. If you invested in Biogen, you are encouraged to obtain additional information by visiting ...